Perceptive Advisors’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Perceptive Advisors’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,486,991	Closed	-$31.9M	–	132
2024 Q1	$31.9M	Hold	1,486,991	–	–	0.56%	52
2023 Q4	$5.44M	Hold	1,486,991	–	–	0.12%	75
2023 Q3	$5.77M	Hold	1,486,991	–	–	0.19%	67
2023 Q2	$6.26M	Sell	1,486,991 -1	-0%	-$3	0.18%	73
2023 Q1	$4.43M	Hold	1,486,992	–	–	0.13%	77
2022 Q4	$7.43M	Hold	1,486,992	–	–	0.21%	64
2022 Q3	$9.66M	Hold	1,486,992	–	–	0.28%	67
2022 Q2	$10.8M	Hold	1,486,992	–	–	0.34%	59
2022 Q1	$21.9M	Hold	1,486,992	–	–	0.44%	54
2021 Q4	$71.4M	Hold	1,486,992	–	–	1.1%	23
2021 Q3	$217M	Hold	1,486,992	–	–	3.15%	7
2021 Q2	$172M	Hold	1,486,992	–	–	2.23%	10
2021 Q1	$141M	Buy	+1,486,992	New	+$194M	1.78%	15

Perceptive Advisors's LABP Position: Q2 2024 in Review

Perceptive Advisors sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 1,486,991 shares — an estimated $31.9M sold.

Perceptive Advisors first reported a position in LABP in Q1 2021 and held it in 13 quarters. The position peaked at $217M in Q3 2021. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.

Perceptive Advisors reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Perceptive Advisors sold 1,486,991 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $31.9M.
Perceptive Advisors first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
Perceptive Advisors's Landos Biopharma, Inc. Common Stock position peaked at $217M in Q3 2021.
0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.